Zentiva Continues Its Expansion In Oncology With The Launch Of ALYMSYS® (bevacizumab) In 21 Countries Across Europe

Our Bureau

Zentiva and mAbxience announce their collaboration for the launch of the ALYMSYS® (bevacizumab) following its European Marketing Authorisation on March 26th. The EC approval is based on a comprehensive clinical and scientific package which demonstrated biosimilarity of ALYMSYS® to the originator reference product.

Nick Haggar, Chief Executive Officer of Zentiva stated: “We are very proud to take a further step in growing our Oncology medicines portfolio while realizing our ambition to increase the access to biologic medicines across Europe. Biologic medicines play a central role in the fight against cancer and our partnership with mAbxience marks an important milestone in the growth of Zentiva and the contribution we can make to public health across Europe.”

A biosimilar medicinal product is a biological medicine that is highly similar to the reference medicinal product with regard to quality, safety, and efficacy. Biosimilars can contribute to an increase in the number of patients gaining access to biological treatments while offering significant cost savings for healthcare systems.

ALYMSYS® will be marketed by Zentiva in 21 countries across Europe.


Leave a Reply

Your email address will not be published. Required fields are marked *

Next Post

Copan, putting Covid-19 challenges behind and setting up for the post-pandemic scenario

With an email to the main distributors, Copan group’s CEO describes how the ramp-up of Covid-19-related products has been concluded, and how the company is now reorganizing to face post-pandemic challenges. Last Tuesday, Copan partners received an email signed by Copan’s CEO Stefania Triva herself. Certainly, it was not the first email […]

Subscribe Now